-
公开(公告)号:US10905772B2
公开(公告)日:2021-02-02
申请号:US15872841
申请日:2018-01-16
Applicant: AMGEN INC.
Inventor: Yuan Cheng , Chawita Netirojjanakul , Jerry Ryan Holder , Bin Wu , James R. Falsey , Bradley J. Herberich , Kelvin Sham , Leslie P. Miranda , Shu-Chen Lu , Murielle M. Veniant-Ellison , Shanaka Stanislaus , Junming Yie , Jing Xu
IPC: A61K47/68 , A61K38/26 , A61P3/10 , C07K16/28 , A61K39/395
Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.
-
2.
公开(公告)号:US12252540B2
公开(公告)日:2025-03-18
申请号:US17332578
申请日:2021-05-27
Applicant: AMGEN INC.
Inventor: Junming Yie , Donghui Shi , David J. Lloyd , Jinghong Wang , Glenn N. Sivits, Jr. , Murielle M. Veniant-Ellison , Renee Komorowski , Neeraj Agrawal , Darren L. Bates , Brandon C. P. Clavette , Ian N. Foltz , Shu-yin Ho , Christopher Murawsky , Xiaoshan Min , Zhulun Wang
Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
-
3.
公开(公告)号:US12060430B2
公开(公告)日:2024-08-13
申请号:US17332578
申请日:2021-05-27
Applicant: AMGEN INC.
Inventor: Junming Yie , Donghui Shi , David J. Lloyd , Jinghong Wang , Glenn N. Sivits, Jr. , Murielle M. Veniant-Ellison , Renee Komorowski , Neeraj Agrawal , Darren L. Bates , Brandon C. P. Clavette , Ian N. Foltz , Shu-yin Ho , Christopher Murawsky , Xiaoshan Min , Zhulun Wang
CPC classification number: C07K16/2869 , A61K9/0019 , A61K38/1703 , A61K38/26 , A61K39/3955 , A61K2039/505 , A61K2039/54 , C07K2299/00 , C07K2317/21 , C07K2317/32 , C07K2317/33 , C07K2317/41 , C07K2317/52 , C07K2317/71 , C07K2317/76 , C07K2317/92 , A61K39/3955 , A61K2300/00
Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
-
公开(公告)号:US10336798B2
公开(公告)日:2019-07-02
申请号:US15625891
申请日:2017-06-16
Applicant: Amgen Inc.
Inventor: Yumei Xiong , Yi Zhang , Jackie Z. Sheng , Agnes Eva Hamburger , Murielle M. Veniant-Ellison , Grant Shimamoto , Xiaoshan Min , Zhulun Wang , Jie Tang , Gunasekaran Kannan , Kenneth W. Walker , Bryan Lemon
IPC: A61K38/00 , A61K38/16 , A61K38/17 , A61K38/18 , C07K14/475 , C07K14/495 , C07K14/51 , A61K39/00
Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
公开(公告)号:US20170233467A1
公开(公告)日:2017-08-17
申请号:US15518714
申请日:2015-10-16
Applicant: AMGEN INC.
Inventor: Shu-Chen Lu , Murielle M. Veniant-Ellison , Jing Xu , Hossein Salimi-Moosavi , Jonathan Daniel Oliner
IPC: C07K16/22
CPC classification number: C07K16/22 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/31 , C07K2317/55 , C07K2317/76
Abstract: The present disclosure provides methods of treating ocular disorders using anti-angiogenic antibodies and pharmaceutical formulations.
-
公开(公告)号:US11739131B2
公开(公告)日:2023-08-29
申请号:US16416050
申请日:2019-05-17
Applicant: Amgen Inc.
Inventor: Yumei Xiong , Yi Zhang , Jackie Z. Sheng , Agnes Eva Hamburger , Murielle M. Veniant-Ellison , Grant Shimamoto , Xiaoshan Min , Zhulun Wang , Jie Tang , Gunasekaran Kannan , Kenneth W. Walker , Bryan Lemon
IPC: C07K14/475 , C07K14/495 , C07K14/51 , A61K38/16 , A61K38/00 , A61K38/18 , A61K38/17 , A61K39/00
CPC classification number: C07K14/475 , A61K38/00 , A61K38/16 , A61K38/17 , A61K38/18 , A61K39/0005 , C07K14/495 , C07K14/51 , A61K2039/6056 , C07K2319/30
Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
公开(公告)号:US11046774B2
公开(公告)日:2021-06-29
申请号:US16285118
申请日:2019-02-25
Applicant: AMGEN INC.
Inventor: Junming Yie , Donghui Shi , David J. Lloyd , Jinghong Wang , Glenn N. Sivits, Jr. , Murielle M. Veniant-Ellison , Renee Komorowski , Neeraj Agrawal , Darren L. Bates , Brandon C. P. Clavette , Ian N. Foltz , Shu-yin Ho , Christopher Murawsky , Xiaoshan Min , Zhulun Wang
Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
-
公开(公告)号:US10894814B2
公开(公告)日:2021-01-19
申请号:US15826442
申请日:2017-11-29
Applicant: Amgen Inc.
Inventor: Yumei Xiong , Yi Zhang , Jackie Z. Sheng , Agnes Eva Hamburger , Murielle M. Veniant-Ellison , Grant Shimamoto , Xiaoshan Min , Zhulun Wang , Jie Tang , Gunasekaran Kannan , Marissa Mock , Kenneth William Walker
IPC: C07K14/475
Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
公开(公告)号:US20190276546A1
公开(公告)日:2019-09-12
申请号:US16285118
申请日:2019-02-25
Applicant: AMGEN INC.
Inventor: Junming Yie , Donghui Shi , David J. Lloyd , Jinghong Wang , Glenn N. Sivits, JR. , Murielle M. Veniant-Ellison , Renee Komorowski , Neeraj Agrawal , Darren L. Bates , Brandon C. P. Clavette , Ian N. Foltz , Shu-yin Ho , Christopher Murawsky , Xiaoshan Min , Zhulun Wang
IPC: C07K16/28 , A61K9/00 , A61K38/26 , A61K39/395 , A61K38/17
Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
-
公开(公告)号:US10294303B2
公开(公告)日:2019-05-21
申请号:US15387542
申请日:2016-12-21
Applicant: AMGEN INC.
Inventor: Junming Yie , Donghui Shi , David J. Lloyd , Jinghong Wang , Glenn N. Sivits, Jr. , Murielle M. Veniant-Ellison , Renee Komorowski , Neeraj Agrawal , Darren L. Bates , Brandon C. P. Clavette , Ian N. Foltz , Shu-yin Ho , Christopher Murawsky , Xiaoshan Min , Zhulun Wang
Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
-
-
-
-
-
-
-
-
-